

## *dupA*<sub>1</sub> Is Associated with Duodenal Ulcer and High Interleukin-8 Secretion from the Gastric Mucosa

We read with interest the recent article by Jung et al. addressing the relationship of the *dupA* gene cluster with clinical outcomes and gastric mucosal interleukin 8 (IL-8) secretion (4). It was found that *Helicobacter pylori* infection with strains possessing a complete *dupA* cluster increased duodenal ulcer risk compared to that with *H. pylori* infection with strains with an incomplete *dupA* cluster or without the *dupA* gene. Findings were independent of the *cag* pathogenicity island (PAI) status. It was also found that gastric mucosal IL-8 levels were significantly higher in the complete *dupA* cluster group than in the incomplete *dupA* cluster group or the group without the *dupA* gene (4).

Using the same methodology described in Jung et al., we studied the relationship between *dupA* cluster genes, clinical outcomes, and gastric mucosal IL-8 levels in 68 (22 duodenal ulcer [DU], 5 gastric ulcer [GU], 41 nonulcer dyspepsia [NUD]) Iraqi samples. The prevalence of *dupA* was 48.4% (33/68), and those of other *vir* gene homologues were 76.5% for *virB8* (52/68), 57.4% for *virB9* (39/68), 67.6% for *virB10* (46/68), 77.9% for *virB11* (53/68), 52.9% for *virD4* (36/68), and 73.5% for *virD2* (50/68) (Table 1). In contrast with Jung et al.'s report, none of the *H. pylori* strains possessed all 6 *vir* gene homologues. We did not observe associations between the presence of the *dupA* gene and clinical outcomes; this result is consistent with results from other countries, such as Brazil and Iran (1, 3). As *dupA* was previously classified into *dupA*<sub>1</sub> (functional) and *dupA*<sub>2</sub> (nonfunctional, including the original form described in which the open reading frame was broken by a stop codon) (2), we sequenced *dupA* genes from a collection of *H. pylori* strains isolated in Iraq as described previously (2). A total of 33% (11/33; 8 DU, 0 GU, 3 NUD) of *dupA*-positive Iraqi strains typed as *dupA*<sub>1</sub>. A significant association was observed between *dupA*<sub>1</sub> and DU ( $P < 0.01$ ). This result may indicate that *dupA*<sub>1</sub> is important in DU development. Therefore, *dupA* polymorphisms may explain the contradictory association between *dupA* and clinical outcomes, and this may be more important than an intact *dupA* gene cluster.

TABLE 1 The prevalence of *dupA* and *vir* genes in 68 Iraqi strains<sup>a</sup>

Gene	No. of strains (%) in each group containing the indicated gene			
	All	DU	GU	NUD
<i>virB8</i>	52 (76.5)	19 (86.4)	5 (100.0)	28 (68.3)
<i>virB9</i>	39 (57.4)	13 (59.1)	3 (60.0)	23 (56.1)
<i>virB10</i>	46 (67.6)	15 (68.2)	1 (20.0)	30 (73.2)
<i>virB11</i>	53 (77.9)	15 (68.2)	5 (100.0)	33 (80.5)
<i>virD4</i>	36 (52.9)	14 (63.6)	2 (40.0)	20 (48.8)
<i>virD2</i>	50 (73.5)	13 (59.1)	1 (20.0)	36 (87.8)
<i>dupA</i>	33 (48.5)	12 (54.5)	2 (40.0)	19 (46.3)

<sup>a</sup> The 68 strains were composed of 22 DU, 5 GU, and 41 NUD.




FIG 1 IL-8 secretion from the gastric mucosae of patients infected with *H. pylori*. Error bars indicate the standard deviation. Gastric mucosal IL-8 levels were significantly higher in patients carrying *dupA*<sub>1</sub> than in other groups.

Additionally, we studied gastric mucosal levels of IL-8. We classified our patients into 3 groups according to *dupA* status: patients carrying *dupA*<sub>1</sub> strains, those with *dupA*<sub>2</sub> strains, and those with *dupA*-negative strains. Gastric mucosal IL-8 levels were significantly higher in patients carrying *dupA*<sub>1</sub> strains than in the other groups (*dupA*<sub>1</sub>, 55.6 ± 8.6 pg/mg; *dupA*<sub>2</sub>, 27 ± 1.7 pg/mg; *dupA* negative, 28.6 ± 3.4 pg/mg;  $P < 0.05$ ) (Fig. 1). These findings suggest that *dupA*<sub>1</sub> is important in IL-8 production in the gastric mucosa.

In conclusion, classification of *dupA* into *dupA*<sub>1</sub> (functional) and *dupA*<sub>2</sub> (nonfunctional), rather than either *dupA* status or the presence of an intact *dupA* gene cluster, correlates with clinical outcome and gastric IL-8 levels in Iraqi *H. pylori* infection. Further research is needed to investigate the role of *dupA* in *H. pylori*-associated disease development.

### ACKNOWLEDGMENTS

We are grateful to John Atherton and Karen Robinson for their help and support during this work. We thank Karwan Fendi and Halat Majed for their excellent technical assistance.

We have no conflicts of interest to declare.

### REFERENCES

- Gomes LI, et al. 2008. Lack of association between *Helicobacter pylori* infection with *dupA*-positive strains and gastroduodenal diseases in Brazilian patients. *Int. J. Med. Microbiol.* 298:223–230.
- Hussein NR, et al. 2010. *Helicobacter pylori dupA* is polymorphic, and its active form induces proinflammatory cytokine secretion by mononuclear cells. *J. Infect. Dis.* 202:261–269.
- Hussein NR, et al. 2008. Differences in virulence markers between *Helico-*

Editor: S. R. Blanke

Address correspondence to Nawfal R. Hussein, Nawfal.hussein@yahoo.com.

For the author reply, see doi:10.1128/IAI.00273-12.

Copyright © 2012, American Society for Microbiology. All Rights Reserved.

doi:10.1128/IAI.00076-12

*bacter pylori* strains from Iraq and those from Iran: potential importance of regional differences in *H. pylori*-associated disease. *J. Clin. Microbiol.* **46**: 1774–1779.

4. Jung SW, Sugimoto M, Shiota S, Graham DY, Yamaoka Y. 2012. The intact *dupA* cluster is a more reliable *Helicobacter pylori* virulence marker than *dupA* alone. *Infect. Immun.* **80**:381–387.

**Nawfal R. Hussein**

Clinical Microbiology and Infection Control Department  
Azadi Teaching Hospital and the Department of Microbiology  
School of Medicine  
Faculty of Medical Sciences  
University of Duhok  
Kurdistan Region, Iraq

**Shahlaa M. Abdullah**

Genomic Centre  
Koya University  
Koya, Kurdistan Region, Iraq

**Azad M. Salih**

Clinical Microbiology and Infection Control Department  
Azadi Teaching Hospital and the Department of Microbiology  
School of Medicine  
Faculty of Medical Sciences  
University of Duhok  
Kurdistan Region, Iraq

**Mahde A. Assafi**

The Centre for Biomolecular Sciences  
University of Nottingham  
Nottingham, United Kingdom